Management and treatment of patients with dilated cardiomyopathy: State of the art;Marcadores de la actuacion clinica en pacientes con miocardiopatia dilatada

Revista Espanola de Cardiologia

Volumn 49, Issue 9, 1996, Pages 682-692

  Anguita, Manuel ^a   Torres, Francisco ^b   Vallés, Federico ^a  

^a Hospital Universitario Reina Sofia Cordoba   (Argentina)

^b HOSPITAL COSTA DEL SOL   (Spain)

Author keywords

dilated cardiomyopathy; heart failure

Indexed keywords

AMLODIPINE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CAPTOPRIL; DIGITALIS; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FELODIPINE; FIBRINOLYTIC AGENT; GLYCERYL TRINITRATE; HYDRALAZINE; INOTROPIC AGENT; LISINOPRIL; MILRINONE; NISOLDIPINE; NITROPRUSSIDE SODIUM; PIPERANOMETOZINE; RAMIPRIL; TRANDOLAPRIL; VASODILATOR AGENT; XAMOTEROL;

CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; HEART TRANSPLANTATION; HIGH RISK POPULATION; HUMAN; PROGNOSIS; REVIEW; RISK FACTOR; SYMPTOMATOLOGY; CONGESTIVE CARDIOMYOPATHY;

CARDIOMYOPATHY, DILATED; HEART FAILURE, CONGESTIVE; HEART TRANSPLANTATION; HUMANS; PROGNOSIS;

EID: 0030228656     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Report of the WHO/ISFC task force on the definition and classification of cardiomyopathies. Br Heart J 1980; 44: 672-673
2. Coughlin SS, Szklo M, Baughman K, Pearson TA. The epidemiology of idiopathic dilated cardiomyopathy in a biracial community. Am J Epidemiol 1990; 131: 48-56.
3. Hartz AJ, Anderson AJ, Brooks HL, Manley JC, Parent GT, Barboriak JJ. The association of smoking with cardiomyopathy. N Engl J Med 1984; 311: 1.201-1.206.
4. Archard LC, Bowles NE, Olsen EGJ, Richardon PJ. Detection of persistent coxsackie B virus RNA in dilated cardiomyopathy and myocarditis. Eur Heart J 1987; 8 (Supl J): 437-440
5. Vallés F, Anguita M, Arizón JM, Latre JM, Giménez D, Torres F et al. Factors predicting long-term outcome in patients with acute myocarditis. J Am Coll Cardiol 1994; 23 (Supl): 364A.
6. Parrillo JE, Cunnion RE, Epstein SE. A prospective, randomized controlled trial of prednisone for dilated cardiomyopathy. N Engl J Med 1989; 321: 1.061-1.068.
7. Latham RD, Mulrow JP, Virmani R, Robinowitz M, Moody JM. Recently diagnosed idiopathic dilated cardiomyopathy: incidence of myocarditis and efficacy of prednisone therapy. Am Heart J 1989; 117. 876-882.
8. Sugrue DD, Rodeheffer RJ, Codd MB, Ballard DJ, Fuster V, Gersh BJ. The clinical course of idiopathic dilated cardiomyopathy: a population-based study. Ann Intern Med 1992; 117: 117-123.
9. Fuster V, Gersh BJ, Giuliani ER, Tajik AJ, Brandenburg RO, Frye RL. The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol 1981; 47. 525-531.
10. Díaz RA, Obasohan A, Oakley CM. Prediction of outcome in dilated cardiomyopathy. Br Heart J 1987; 58: 393-399.
11. Johnson RA, Palacios I. Dilated cardiomyopathies of the adult N Engl J Med 1982; 307: 1.051-1.058.
12. Komadja M, Jais P, Reeves F. Factors predicting mortality in idiopathic dilated cardiomyopathy. Eur Heart J 1990; 11: 824-831.
13. Di Lenarda A, Lardieri G, Mestroni L. Dilated cardiomyopathy: changing survival in the last 20 years. Circulation 1990; 82 (Supl 3): 387
14. Ikram H, Williamson HG, Won M, Crozier IG, Wells EJ. The course of idiopathic dilated cardiomyopathy in New Zeland. Br Heart J 1987; 57: 521-527.
15. Unverferth D, Magorien R, Moeschberger M, Baker P, Fetters J, Leier C. Factors influencing the one year mortality of dilated cardiomyopathy. Am J Cardiol 1984; 54: 147-152.
16. Cleland J, Dargie H, Ford I. Mortality in heart failure: clinical variables of prognostic value. Br Heart J 1987; 577-582.
17. De María R, Gavazzi A, Caroli A, Ometto R, Biagini A, Camerini F. Ventricular arrhythmias in dilated cardiomyopathy as an independent prognostic hallmark. Am J Cardiol 1992; 69: 1.451-1.457.
18. Dec GW, Fuster V. Idiopathic dilated cardiomyopathy. N Engl J Med 1994; 331: 1.564-1.575.
19. Mason JW, O'Connell JB. Clinical merit of endomyocardial biopsy. Circulation 1989; 79: 971-979.
20. Popma JJ, Cigarroa RG, Buja LM, Hillis LD. Diagnostic and prognostic utility of right-sided catheterization and endomyocardial biopsy in idiopathic dilated cardiomyopathy. Am J Cardiol 1989; 63: 955-958.
21. Zee-Cheng CS, Tsai CC, Palmer DC, Codd JE, Pennington DG, Williams GA. High incidence of myocarditis by endomyocardial biopsy in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1984; 3: 63-70.
22. Dec GW, Palacios I, Yasuda T. Antimyosin antibody cardiac imaging: its role in the diagnosis of myocarditis. J Am Coll Cardiol 1990; 16: 97-104.
23. Anguita M, Arizón JM, Bueno G, Concha M, Vallés F. Spontaneous clinical and hemodynamic improvement in patients on waiting list for heart transplantation. Chest 1992; 102: 96-99.
24. Figulla HR, Rahlf G, Nieger M, Luig H, Kreuzer H. Spontaneous hemodynamic improvement or stabilization and associated biopsy finding in patients with congestive cardiomyopathy. Circulation 1985; 71: 1.095-1.104.
25. Rouillard VM, Fishbein MC, Coy K, Don Michael TA, Siegel RJ. Is idiopathic dilated cardiomyopathy a reversible condition? J Am Coll Cardiol 1991; 17 (Supl A): A219.
26. Diamond I. Alcoholic myopathy and cardiomyopathy. N Engl J Med 1989; 72: 458-460.
27. Regan JT. Alcoholic cardiomyopathy. Prog Cardiovasc Dis 1984; 28: 141-152.
28. Vallés F, Anguita M, Arizón JM. Terapéutica actual de la insuficiencia cardíaca. En: Iñíguez A, editor. Tratado de terapéutica farmacológica. Madrid: Ela SL, 1995; 85-104.
29. Dunkman WB, Johnson GR, Carson PE, Bhat G, Farrell L, Cohn JN. Incidence of thromboembolic events in congestive heart failure. Circulation 1993; 87 (Supl 6): 94-101.
30. Falk RH, Foster E, Coats MH. Ventricular thrombi and thromboembolism in dilated cardiomyopathy: a prospective follow-up study. Am Heart J 1992; 123: 136-142.
31. Cleland JGF, Dargie HJ, Finflay IN, Wilson JT. Clinical, hemodynamic and antiarrhythmic effects of long-term treatment with amiodarone of patients in heart failure. Br Heart J 1987; 57: 436-445.
32. Hamer AWF, Arkles LB, Johns JA. Beneficial effects of low-dose amiodarone m patients with congestive heart failure: a placebo-controlled trial. J Am Coll Cardiol 1989; 14: 1.768-1.774.
33. Nicklas JM, McKenna WJ, Stewart RA. Prospective, double-blind, placebo-controlled trial of low-dose amiodarone in patients with severe heart failure and asymptomatic frequent ventricular ectopy. Am Heart J 1991; 122. 1.016-1.021.
34. Poll DS, Marchlinski FE, Buxton AE, Josephson ME. Usefulness of programmed stimulation in idiopathic dilated cardiomyopathy. Am J Cardiol 1986, 58: 992-997.
35. Sweeny MO, Ruskin JN. Mortality benefits and the implantable cardioverter-defibrillator. Circulation 1994; 89: 1.851-1.858.
36. Cohn JN, Johnson G, Ziesche S, Cobb FR, Francis G, Tristani F et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303-310.
37. Chadda K, Goldstein S, Byrington R, Curb JD. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation 1986; 73: 503-510
38. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685-691.
39. The captopril-digoxin multicenter research group. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure JAMA 1988; 259: 539-544.
40. Kleber FX, Niemoller L, Doering W. Impact of converting enzyme inhibition on progression of chrome heart failure: results of the Munich Mild Heart Failure trial. Br Heart J 1992; 67: 289-296.
41. Anguita M. Lecciones de los ensayos clínicos en insuficiencia cardíaca congestiva. Rev Esp Cardiol 1995, 48: 699-709.
42. Garg R, Yusuf S. Current and ongoing randomized trials in heart failure and left ventricular dysfunction. J Am Coll Cardiol 1993; 22 (Supl A): 194A-197A.
43. The SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 1991; 325. 293-302.
44. The CONSENSUS Trial Study Group. Effect of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study. N Engl J Med 1987; 316: 1.429-1.435.
45. Fonarow GC, Chelimski-Fallick C, Stevenson LW. Effect of direct vasodilation with hydralazine versus angiotensin converting enzyme inhibition with captopril on mortality in advanced heart failure: the HyC trial. J Am Coll Cardiol 1992; 19: 842-850.
46. Pouleur H, Rousseau MF, Oakley C, Ryden L, for the Xamoterol in Severe Heart Failure Study Group. Differences in mortality between patients treated with captopril and enalapril in the Xamoterol in Severe Heart Failure Study Group. Am J Cardiol 1991; 68: 71-74.
47. Anguita M, Arizón JM, Bueno G, Latre JM, Sancho M, Torres F et al. Clinical and hemodynamic predictors of survival in patients aged < 65 years with severe congestive heart failure secondary to ischemic or nonischemic dilated cardiomyopathy. Am J Cardiol 1993; 72: 413-417.
48. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani F et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administra-tion Cooperative Study. N Engl J Med 1986, 314: 1.547-1.552.
49. Eichhorn EJ. The paradox of betaadrenergic blockade for the management of congestive heart failure. Am J Med 1992; 92: 527-538.
50. Feldman AM, Bristow MR, Parmley WW, Carson PE, Pepine CJ, Gilbert EM et al. Effects of vesnarinona on morbidity and mortality in patients with heart failure. N Engl J Med 1993; 329: 149-155.
51. Packer M, Gheorghiade M, Young JB, Constantini PJ, Adams KF, Cody RJ et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin converting enzyme inhibitors, RADIANCE Study. N Engl J Med 1993; 329: 1-7.
52. Uretsky BF, Young JB, Shahidi FE, Yellen LG, Harrison MC, Jolly MK et al. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. J Am Coll Cardiol 1993; 22: 955-962.
53. Soler-Soler J. Vigencia actual del tratamiento con digital en la insuficiencia cardíaca. Rev Esp Cardiol 1992; 45: 531-536.
54. Stevenson LW, Drakup KA, Tillisch JH. Efficacy of medical therapy tailored for severe congestive heart failure in patients transferred for urgent heart transplantation. Am J Cardiol 1989; 63: 461-464.
55. Swedberg K. Initial experience with betablockers in dilated cardiomyopathy. Am J Cardiol 1993; 71: 30C-38C.
56. Poole-Wilson PA. Relation of pathophysiologic mechanism to outcome in heart failure. J Am Coll Cardiol 1993; 22 (Supl A): 22A-29A.
57. Benedict CR, Weiner DH, Johnstone DE, Bourassa MG, Ghali JK, Nicklas J et al. Comparative neurohormonal responses in patients with preserved and impaired left ventricular ejection fraction: results of the SOLVD Registry. J Am Coll Cardiol 1993; 22 (Supl A): 146-153.
58. Xie GY, Berk MR, Smith MD, Gurley JC, DeMaria AN. Prognostic value of Doppler transmitral flow patterns in patients with congestive heart failure. J Am Coll Cardiol 1994, 24; 132-139.
59. Crespo MG, Escaned J Valoración funcional del paciente en insuficiencia cardíaca. Indicadores pronósticos. Monocardio 1995; 39: 65-75.
60. Anguita M, Arizón JM, Giménez D, Torres F, Vallés F. Incidence and predictors of sudden death in patients with severe heart failure. Eur Heart J 1992; 13 (Supl): 291.
61. Vallés F, Anguita M, Arizón JM, Torres F, Giménez D, López-Granados A et al. Long-term outcome of patients with end stage heart failure established on medical therapy. Eur Heart J 1994; 15 (Supl): 540.
62. Anguita M, Arizón JM, Vallés F, Torres F, Giménez D, Concha M et al. Influence of heart transplantation on the natural history of patients with severe congestive heart failure. J Heart Lung Transplant 1993; 12: 974-982.